TVTX: Wedbush Raises Target
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.